New antibody cocktail targets stubborn liver disease after stem cell transplants
NCT ID NCT06364319
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a lab-made antibody called anti-CD25 rhMAb for people with chronic graft-versus-host disease (cGVHD) of the liver that hasn't improved with steroids. The antibody is given alongside standard immune-suppressing drugs. The trial will include 30 adults aged 16-65 who have had a stem cell transplant. The goal is to see if this combination can shrink liver damage and control the disease better than current options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
anti-CD25 rhMAb (a lab-made antibody) combined with prednisone, ruxolitinib, and cyclosporine
What this could lead to
If it works, this could offer a new treatment option for people with severe liver graft-versus-host disease that hasn't responded to steroids.
What could go wrong
This is a small, early-phase trial with only 30 people, so results may not apply to everyone. The treatment also requires ongoing immune-suppressing drugs, which carry risks of infection and other side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CGVHD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.